Adlyxin Starter Pack
Name: Adlyxin Starter Pack
- Adlyxin Starter Pack side effects
- Adlyxin Starter Pack effects of adlyxin starter pack
- Adlyxin Starter Pack drug
- Adlyxin Starter Pack adult dose
- Adlyxin Starter Pack injection
What are some other side effects of Adlyxin Starter Pack?
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
- Upset stomach or throwing up.
- Loose stools (diarrhea).
These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.
How do I store and/or throw out Adlyxin Starter Pack?
- Store unopened pens in a refrigerator. Do not freeze.
- Store in original container.
- Store opened pens at room temperature. Throw away any part not used after 2 weeks.
- Take off the needle after each shot. Do not store this device with the needle on it.
- Keep the cap on the pen when not in use.
- Protect from light.
- Do not use if Adlyxin Starter Pack (lixisenatide) is out of date.
- Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
- Check with your pharmacist about how to throw out unused drugs.
Usual Adult Dose for Diabetes Type 2
Initial dose: 10 mcg subcutaneously once a day for 14 days
Maintenance dose: Increase to 20 mcg subcutaneously once a day on day 15, and thereafter
-This drug should be administered within 1 hour before the first meal of the day, preferably the same meal each day; if a dose is missed, administer within 1 hour prior to the next meal.
-Concurrent use with short acting insulin has not been studied and is not recommended.
Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Not recommended in patients with ESRD
-Administer subcutaneously in the abdomen, thigh, or upper arm
-Give injection once a day one hour before the first meal of the day, preferably the same meal every day.
-If a dose is missed, give within 1 hour prior to the next meal.
-Rotate injections with each dose
-Pen devices should not be shared between patients, even if the pen needle is changed
-Prior to first use:
-Store at 36 to 46F (2C to 8C); do not freeze; do not use if it has been frozen
-Keep pen in original package to protect from light
-After first use:
-Store below 86F (30C); discard 14 days after first use
-Replace pen cap after each use to protect from light
Reconstitution/preparation techniques: Patients should receive proper training from their healthcare provider prior to first use. See product labeling for specific instructions.
-This drug should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
-The concurrent use of short-acting insulin has not been studied and is not recommended.
-Patients may develop antibodies to this drug; this should be considered in patients who have worsening glycemic control, significant injection site reactions or allergic reactions.
-Renal function should be monitored when initiating or escalating doses in patients with renal impairment and in patients with severe gastrointestinal reactions.
-Blood glucose and hemoglobin A1C measurements should be measured periodically to assess efficacy.
-Observe for signs and symptoms of pancreatitis
-Patients should be advised to never share a pen with another person, even if the needle is changed; patients should understand that sharing needles or syringes with another person carries a risk for transmission of blood-borne pathogens
-Patients should be aware of the potential for gastrointestinal reactions and take measures to ensure adequate fluid intake to avoid dehydration and to seek medical advice for persistent and severe events.
-Patients should be instructed to seek medical advice during periods of stress as medical management of diabetes may change.
-Inform patients that hypersensitivity reactions may occur; patients should be instructed to contact their health care professional.
-Patients should be advised their risk of hypoglycemia is increased if they use this drug in combination with a sulfonylurea or basal insulin.
-Patients should be aware of signs and symptoms of hypoglycemia and how it should be managed; patients should be advised to take precautions to avoid hypoglycemia while driving and using machines